Photocure マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Dan Schneider

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	6yrs
CEOの所有権	0.4%
経営陣の平均在職期間	6yrs
取締役会の平均在任期間	1.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Dan Schneider

6yrs

在職期間

Mr. Daniel Schneider, also known as Dan, joined Photocure ASA since November 2018 and has been President & CEO of PhotoCure ASA since November 1, 2018. He has been Vice President of Sales at Pernix Sleep,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Daniel Schneider	President & CEO	6yrs	データなし	0.37% $ 444.1k
Erik Dahl	Chief Financial Officer	12.3yrs	データなし	0.12% $ 145.9k
David Moskowitz	Head of Investor Relations	no data	データなし	データなし
Anja Gossens-von der Heidt	Head of Global Human Resources	no data	データなし	データなし
Anders Neijber	Chief Medical Officer of Global Medical Affairs	2.2yrs	データなし	データなし
Tolv Hillestad	Group Controller	no data	データなし	データなし

6.0yrs

平均在職期間

経験豊富な経営陣: PHCU.Fの経営陣は経験豊富で経験豊富です（平均在職期間は6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Johanna Holldack	Independent Director	7.6yrs	データなし	データなし
Neal Shore	Independent Director	no data	データなし	データなし
Dylan Hallerberg	Independent Chairman	1.8yrs	データなし	0.55% $ 668.2k
Ghizlane Tagmouti	Director	less than a year	データなし	データなし
Malene Brandborg	Independent Director	no data	データなし	データなし

1.8yrs

平均在職期間

経験豊富なボード: PHCU.Fの取締役会は経験豊富ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Photocure マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Photocure ASA Announces Board Appointments

Photocure ASA Announces Change of Board Composition

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Recent updates

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /14